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Abstract: 
Background: 
Congenital cytomegalovirus (CMV) infection is the leading infectious cause of birth defects, 
mental retardation and non-genetic sensorineural hearing loss. Murine models have been 
developed in order to understand the pathophysiological mechanisms underlying these 
lesions. These models are being proposed for the validation of therapeutic protocols for 
clinical use. The aim of this preclinical study was to assess the pharmacokinetics of the 
reference antiviral molecule, ganciclovir, in order to optimize these protocols and confirm the 
diffusion of the molecule to the appropriate target zones. 
Methods:  
Transplacental and intracochlear diffusion of ganciclovir was evaluated in mice and rats. 
Pharmacokinetics was assessed in adult mice and pups after 5 consecutive days of 
intraperitoneal injection of ganciclovir. The occurrence of hematological side effects of 
ganciclovir was evaluated in the different blood cell lineages. 
Results:  
In adult rats, the intracochlear diffusion of ganciclovir was shown to achieve the same 
concentration as in blood. In gestating mice, transplacental diffusion was observed, with a 
fetal-to-maternal blood ratio of 0.5. In newborn mice, the plasma concentration profile of 
ganciclovir showed a peak at 2 hours followed by a gradual decrease. In adult mice, the 
concentration peaked at 1 hour, but became undetectable by 2 hours after injection. 
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Counts of white blood cells, red blood cells and platelets decreased significantly in 
ganciclovir-treated newborn mice. 
Conclusion:  
Our data provide evidence for the intracochlear diffusion of the molecule, which may be 
relevant for the treatment of sensorineural hearing loss in congenitally-infected children. 
 
 
Introduction: 
Congenital cytomegalovirus (CMV) infection is the leading infectious cause of congenital 
malformations, mental retardation and deafness in newborns, and is found in 1% of live 
births. Ten to 20% of infected children develop sequelae, of which sensorineural hearing loss 
is the most common. Congenital CMV infection is the second cause of congenital deafness, 
after genetic factors (Benoist et al., 2008; Dollard et al., 2007; Picone et al., 2009). 
The reference treatment for symptomatic neonatal infection is currently the antiviral 
ganciclovir [9 - (1, 3-dihydroxy-2-propoxymethyl) guanine or DPHG], a nucleoside that 
inhibits the in vitro replication of human herpes viruses (Herpes simplex type 1 and type 2, 
CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir is phosphorylated 
to its active form, ganciclovir triphosphate, preferentially in infected cells, with 
concentrations being 10 times lower in uninfected cells (Adler et al., 2007; Barbi et al., 2006). 
Ganciclovir triphosphate exerts its antiviral activity by inhibiting viral DNA synthesis through 
two mechanisms: competitive inhibition of viral DNA polymerases and direct incorporation 
into viral DNA, leading to the blockage of elongation (Donnelly and Brown, 2004). However, 
at therapeutic doses, as a side effect, it inhibits progenitor cell proliferation in the bone 
marrow in direct proportion to its blood concentrations. 
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Murine and guinea pig models in which pups develop sensorineural hearing loss have been 
developed in order to better understand the cochlear and cerebral lesions associated with 
congenital CMV infection in human newborns(Bravo et al., 2003; Donnelly and Brown, 2004; 
Juanjuan et al., 2011; Schachtele et al., 2011). However, in order to study the safety and 
effectiveness of antiviral therapies in limiting these lesions, it is necessary to carry out 
preclinical studies of the pharmacokinetics of these molecules in mouse pups to determine the 
optimal dose and study potential side effects.  
The purpose of this study was therefore to assess the pharmacokinetics and transplacental 
passage of ganciclovir in non-infected pups and adult mice. Several doses of ganciclovir have 
been used in mice (ranging from 15 to 80 mg/kg/day). Here, we chose to use a supraclinical 
dose of 100 mg/kg/day (Duan et al., 1998; Lenzo et al., 2001; Qiao et al., 2011; Shimamura et 
al., 2013), knowing that drug metabolism is higher and its elimination faster in small animals 
than in humans (Martignoni et al., 2006); in comparison, the therapeutic dose in children is 32 
mg/kg/day. We focused especially on the diffusion of ganciclovir into the cochlea, as well as 
its side effects on blood cell lines. 
 
Materials and methods 
 
  1. Animals  
Non-inbred Oncins France 1 (OF1) mice (12 adults, 160 newborn mice, and 1 pregnant 
female) and 2 albino rats non-immunized for MCMV were used (Charles River, France) 
(Table 1). Once in our animal facility, housing and maintenance of animals were carried out 
according to the recommendations of the French National Institute of Health and Medical 
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Research. (Accreditation No. A751901). The experimental protocol was approved by the 
Institut Claude Bernard Ethics Committee in Paris.  
 
2.  Pharmacokinetics in adult mice 
Injection protocol:  
Ganciclovir (Roche, Bale) was diluted in 5% glucose serum (Glucose Monohydrate 5%, 
Lavoisier, Paris) to a concentration of 5 mg/ml and administered intraperitoneally in adult 
mice (40 grams each) at a dose of 50 mg/kg twice a day. A total of five injections was 
administered. 
Samples:  
Twelve adult mice were evaluated.  
Blood samples were collected by intracardiac puncture in adults under isoflurane anesthesia 
before sacrifice, at 1 hour (T1), 2 hours (T2), 3 hours (T3), 4 hours (T4), 6 hours (T6) and 12 
hours (T12) after administration of the 5th and last injection of ganciclovir. 
For each time point, blood samples from 2 adult mice were collected. 
Samples were immediately centrifuged for 10 minutes at 4°C at 10,000 rpm; plasma was 
collected and stored at -20°C until analysis.
 
 
3.  Pharmacokinetics in newborn mice  
Injection protocol:  
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Ganciclovir at a concentration of 5 mg/ml was administered intraperitoneally in newborn 
mice at a dose of 50 mg/kg twice a day,. Five injections were administered in total. 
The mean weight of newborn mice was 2 g on postnatal day 1 (P1), and 4 g at P3. 
Samples:  
One hundred and sixty newborn mice received 5 injections of ganciclovir intraperitoneally at 
12-hour intervals starting on P1. 
Blood samples were taken from mice immediately before sacrifice, at seven time points: 1 
hour (T1), 2 hours (T2), 3 hours (T3), 4 hours (T4), 6 hours (T6), 8 hours (T8) and 12 hours 
(T12) after the last injection of ganciclovir. 
Given the small volume of blood in neonatal mice, for each time point, blood samples from 3 
mice were collected and pooled.  
 
4. Maternal-fetal transfer of ganciclovir  
A pregnant OF1 mouse was selected at E18, 3 days prior to delivery. After being weighed, the 
mouse received a daily dose of 2.5 mg (100 mg/kg/day) of ganciclovir intraperitoneally, 
divided into 2 injections 12 hours apart. Four hours after the 6th injection, the female mouse 
gave birth. The mother and 4 newborn pups were then sacrificed and the following samples 
were collected: blood and kidneys of the mother, blood and brains of the pups.  
 
5. Intracochlear passage of ganciclovir in adult rats 
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After being weighed, two adult rats
 
underwent peritoneal injections. The first rat received 50 
mg/kg of ganciclovir twice a day (i.e. 100 mg/kg/day), for a total of 3 days or 6 injections. 
The second rat was used as a negative control and received intraperitoneal injections of 
glucose solution. After the 6th injection, the two rats were sacrificed; blood and perilymphatic 
fluids were collected immediately after dissection of the cochlea through a transcanal 
approach under microscopic visualization according to the following procedure. After 
retrieval of the eardrum, the promontory was gently fractured and removed, exposing the 
membranous labyrinth. The perilymphatic fluid was removed using a micropipette. The same 
procedure was performed on the contralateral cochlea, and the two samples were pooled 
together in order to obtain the critical volume of 10 µL per rat, the minimum volume required 
for HPLC measurements. Ganciclovir concentrations were measured in the plasma and in the 
perilymphatic fluid in the negative control rat and the ganciclovir-treated rat. 
 
6. Ganciclovir assay 
Concentrations of ganciclovir were determined by HPLC with UV detection at 254 nm. 
Perchloric acid (35% in water) was added to each sample for a final concentration of 3,5% 
and centrifuged to remove protein.  Then 20 µL of cleared supernatant was injected into a a 
150 4.6mm Hypersil ODS 3 mm column (Lindsay, 1987). An HPLC system (Thermo 
Separation Products, Waltham, USA) consisting of a P200 pump, an AS3000 autosampler and 
a UV2000 spectrophotometer was used. The mobile phase consisted of 0.02 M potassium 
dihydrogen phosphate adjusted to pH 3.2 with phosphoric acid, with a flow rate of 1.0 mg/ml. 
The calibration curve for ganciclovir was linear over the range of 0.5–25 mg/mL. The lower 
detection limit was 0.25 mg/mL. K1 and K2 for ganciclovir standards were 2.5 for 2 mg/L and 
15.11 for 15 mg/L respectively.  
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7. Hematological study 
Blood cell counts were performed in newborn mice, in particular in order to investigate the 
presence of neutropenia. Eight newborn mice were treated using the same ganciclovir 
protocol described previously, and eight control newborn mice received saline. 
At the time of sacrifice, blood was collected by intracardiac puncture in an EDTA tube and 
manually agitated to prevent coagulation. The tubes were then promptly sent to the pediatric 
biological hematology department.
 
Cell counts were assessed manually on slides and 
automatically (Procan-PE-6800) when the sample volume permitted. 
 
 
8. Data analysis  
Results are expressed as means ± standard deviation. Student t-test and Mann-Whitney-
Wilcoxon analysis were performed using GraphPad Prism version 5.0 for MacOS (GraphPad 
Software, San Diego, CA; www.graphpad.com). Significance was considered when p < 0.05.  
 
Results   
1. Animals and outcome 
The mortality rate secondary to injections of ganciclovir in neonatal pups was 13.8% (n= 
22/160): hematomas at the site of injection (n=10) and low weight (n=12) were observed in 
dead pups.
 
 
2. Pharmacological study of ganciclovir 
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a.
 
Ganciclovir concentrations and pharmacokinetic profile in adult and neonatal mice 
In adult mice, ganciclovir reached a plasma concentration of 0.81 µg/mL at T1, and was not 
detectable thereafter (Figure 1). 
In neonatal mice, the peak ganciclovir plasma concentration was 6.6 µg/mL at T2; the 
concentration then progressively decreased and was undetectable by T12 (Figure 2). 
b. Bioavailability results 
Maternal-fetal transfer of ganciclovir: Blood concentrations of ganciclovir were similar in the 
mother and pups (6.56 and 5.46 µg/mL respectively). Lower but detectable concentrations 
were measured in the pups' brains and kidneys (1.75 and 2.20 µg/mL respectively).  
Intracochlear transfer: In treated rats, ganciclovir was detectable in the perilymphatic fluid 
(1.8 µg/mL) at approximately half the plasma concentration (3.83 µg/mL). All samples were 
negative in control rats. . 
3. Hematological study 
The effect of ganciclovir was assessed on red blood cells (hemoglobin) (Figure 3A), 
neutrophils (Figure 3B) and platelets (Figure 3C). A significant decrease in hemoglobin, 
neutrophils and platelet was observed in ganciclovir-treated mice compared to controls (p 
<0.05).
 
Discussion:  
Ganciclovir is the reference drug for the management of symptomatic CMV infection, 
including in newborns (Kimberlin et al., 2008). However there are no preclinical studies 
available to improve its administration, in particular to reduce side effects (temporary low 
white blood count). We aimed to provide information on the disposition and potential 
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hematological side effects of ganciclovir in a murine model using supra-therapeutic doses 
administered by the peritoneal route (Donnelly and Brown, 2004; Kimberlin et al., 2008; 
Lackner et al., 2009).  
Our results show that the pharmacokinetics of ganciclovir differ between adult and newborn 
mice, with a higher peak plasma concentration and slower elimination in newborn animals. In 
addition, ganciclovir crosses the placental barrier when injected into gestating mice, with 
plasma concentrations in newborn pups close to maternal concentrations. More importantly, 
ganciclovir can diffuse into the brain and kidneys of pups, as well as the inner ear. The latter 
point was demonstrated in adult rats, as the volume of perilymphatic fluid in mice, especially 
neonates, is too low to allow the accurate measurement of ganciclovir. These data are relevant 
for human patients, and support the use of ganciclovir to treat hearing loss and neurological 
handicap related to congenital CMV infection, where active viral replication persists for 
several years (Sugiura et al., 2003; Teissier et al., 2011; Teissier et al., 2014).  
In human adults, ganciclovir disposition is characterized by linear pharmacokinetics over the 
range of 1.6 to 5 mg/kg (Cymevene, 2011). It is eliminated by glomerular filtration and active 
tubular secretion. In adults with normal renal clearance, the plasma half-life of ganciclovir is 
2.9 +/- 1.3h. However, pharmacokinetic studies are limited in immunodeficient patients with 
severe CMV infections, who receive multiple drugs. In HIV+/CMV+ patients receiving 5 
mg/kg ganciclovir intravenously, the peak plasma concentration is 9.03 +/- 1.42 µg/mL one 
hour after administration and the Cmin is 0.56 µg/mL 11 hours after injection. Diffusion into 
the cerebrospinal fluid has been measured in 2 patients, and attains concentrations between 
0.5 and 0.68 µg/mL, corresponding to 24-67% of the concomitant plasma concentrations 
(Cymevene, 2011).  
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In children, pharmacokinetics has been studied in patients aged 9 months to 12 years with 
normal renal function. The Cmax after twice daily injections of 5 mg/kg is 7.59 +/- 3.21 µg/mL 
on day 1 (Cymevene, 2011). 
In adult mice, pharmacokinetics showed a peak ganciclovir concentration at T1 or earlier but 
concentrations became undetectable at T2, while in pups, the peak concentration occurred at 2 
hours post-injection with a progressive decrease thereafter. Although procedures for drug 
administration and sample collection were standardized, the variability of plasma 
concentrations was probably increased by technical difficulties such as the small sample 
volume obtained for each pup, requiring pooling. Variability could also have been due to 
changes in weight, making precise dosage adjustment difficult.  
The therapeutic effect of ganciclovir is dose-dependent. The selection of the dose tested in the 
present study (100 mg/kg/24h) was guided by doses used in previously published work (Duan 
et al., 1998; Lenzo et al., 2001; Qiao et al., 2011; Shimamura et al., 2013). Although the 
weight-adjusted dose was higher than therapeutic doses in humans (32 mg/kg/24h), a lower 
dose would probably have led to insufficient plasma concentrations, considering the rapid 
elimination of the molecule. Furthermore, systemic concentrations in adult and newborn mice 
were found to be lower than plasma concentrations in humans.  
However, this high dose may have increased side effects (Forster et al., 2010; Shimamura et 
al., 2013). In humans, neutropenia is the most frequent toxic side effect associated with 
ganciclovir and valganciclovir therapy(Marshall and Koch, 2009). To our knowledge, there is 
no study evaluating the side effects of ganciclovir or correlating them to dosage in mice. In 
our study, at the high dose tested, the toxicity of ganciclovir was observed in all blood cell 
lines and may have participated in the mortality rate observed in this series. An in vitro study 
has demonstrated that ganciclovir exhibits duration-dependent toxicity to hematopoietic-
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derived cells in vitro (Janoly-Dumenil et al., 2009). However, mortality was also influenced 
by the occurrence of hematomas at the site of injection and the low birth weight of the 
offspring. These data should be considered when analyzing survival rates in infected animals 
after ganciclovir treatment. Because hematological toxicity is dose-related, the optimization 
of the dosing schedule is required to increase its therapeutic index (Janoly-Dumenil et al., 
2012). 
 
Conclusion:  
Ganciclovir is the antiviral drug of choice currently used in patients with congenital CMV 
infection, yet few if any preclinical studies on its pharmacokinetics exist in the literature. Our 
study has allowed the pharmacokinetics of high-dose ganciclovir to be characterized in a 
murine model. In addition, we have confirmed its transplacental passage in gestating mice as 
well as its diffusion into the brain and the perilymphatic space of the inner ear. However, our 
study has also demonstrated the hematotoxicity of high-dose ganciclovir in different blood 
cell populations in mice. The current challenge in the management of congenital CMV 
infection is to identify effective therapeutic molecules with a satisfactory benefit/side effect 
balance. Other drugs devoid of myelotoxicity, such as maribarvir, are currently under 
evaluation for the prevention of congenital CMV infection in mouse models, but their clinical 
efficacy has not yet been proven. Additional preclinical animal studies using various 
therapeutic doses are therefore necessary to obtain a complete picture of the pharmacokinetics 
and toxicity profiles of these molecules, and design effective treatments to prevent the long-
term sequelae of congenital CMV infection in children.  
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TABLE AND FIGURE LEGENDS 
 
Figure 1: Plasma concentrations of ganciclovir versus time in adult mice following 
intraperitoneal administration at 50mg/kg twice daily. Staring at H2, the ganciclovir 
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concentration passes under detection threshold. The blue line represents the mean 
concentration for each sampling time and bars the standard deviation. 
 
Figure 2: Plasma concentrations of ganciclovir versus time in newborn mice following 
intraperitoneal administration at 50mg/kg twice daily. The blue line represents the mean 
concentration for each sampling time and bars the standard deviation. 
 
Figure 3: Average hemoglobin (A) (g/dl), neutrophils (B) (number/ml) and platelet counts (C) 
(number/ ml) in the treated and control groups. Error bars account for the standard deviation. 
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Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats 
• Transplacental and intracochlear diffusion of gangiclovir in mice and rats: first-time 
proof of inner ear diffusion 
• Pharmacokinetics in adult mice and pups: differences important to consider 
• Ganciclovir toxicity on different cell lineages in mice 
